Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PAH drug shows promise in Long-Term safety study

NCT ID NCT07073820

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 26, 2026 · Updated 2 times

Summary

This study is testing a new medicine called PF-07868489 for people with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lung arteries makes the heart work harder. The study is open-label, meaning everyone knows they are getting the drug, and it follows up on patients from an earlier trial to see how safe and effective the drug is over a longer period. About 36 adults who completed a prior PF-07868489 study will receive a shot every 4 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PF-07868489 (a drug given as a shot under the skin every 4 weeks)
What this could lead to
If it works, this could provide a new long-term treatment option to help control PAH and reduce strain on the heart.
What could go wrong
This is a small, early-phase extension study with only 36 participants, so results may not apply to everyone. The drug's long-term safety and effectiveness are still being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

42 people

The number who actually took part.

Started

Nov 2025

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

This study is seeking participants who are: * aged 18 years or older at screening of the previous study and completed the required treatment duration with PF-07868469 and other assessments at the end of that study. * willing and able to abide with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * do not have worsening or hospitalization for worsening PAH during the qualifying study. * not on placement for a surgery to replace any tissue or part of the body (transplant), and planned surgery for PAH. * do not have an ongoing major health issue in the qualifying study, which in the opinion of the study doctor could make the participant not qualify for this study. * not suffering from or in the past have suffered from hepato-pulmonary syndrome (liver-related lung problem). * not currently prescribed or taking medicines called as GLP-1 agonist.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary arterial hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary hypertension

Contacts and locations

Locations

  • Gachon University Gil Medical Center

    Incheon, Incheon-gwangyeoksi [incheon], 21565, South Korea

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, 510080, China

  • HUB Hôpital Erasme

    Brussels, 1070, Belgium

  • Hammersmith Hospital

    London, Greater London, W12 0HS, United Kingdom

  • Heart and Vascular Center

    San Francisco, California, 94143, United States

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Kobe University Hospital

    Kobe, Hyōgo, 650-0017, Japan

  • Mount Sinai Hospital

    New York, New York, 10029, United States

  • National Hospital Organization Okayama Medical Center

    Okayama, 701-1192, Japan

  • Pulmonary Hypertension Research Queensland Pty Ltd

    Auchenflower, Queensland, 4066, Australia

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, 2050, Australia

  • Samsung Medical Center

    Seoul, Seoul-teukbyeolsi [seoul], 06351, South Korea

  • Seoul National University Hospital

    Seoul, Seoul-teukbyeolsi [seoul], 03080, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, Seoul-teukbyeolsi [seoul], 03722, South Korea

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, 200433, China

  • St. Marianna University Hospital

    Kawasaki, Kanagawa, 216-8511, Japan

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, 410011, China

  • Thoraxklinik-Heidelberg gGmbH

    Heidelberg, Baden-Wurttemberg, 69126, Germany

  • UCSF Health St. Mary's Hospital

    San Francisco, California, 94117, United States

  • UCSF Helen Diller Medical Center at Parnassus Heights

    San Francisco, California, 94143, United States

  • UZ Leuven

    Leuven, 3000, Belgium

  • Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden

    Dresden, Saxony, 01307, Germany

  • Universitaetsklinikum Giessen und Marburg GmbH

    Giessen, Hesse, 35392, Germany

  • Universitätsklinikum Regensburg

    Regensburg, Bavaria, 93053, Germany

  • Universitätsmedizin Greifswald

    Greifswald, Mecklenburg-Vorpommern, 17475, Germany

  • Vseobecna fakultni nemocnice v Praze

    Prague, 12808, Czechia

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, 210009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.